Research ArticleBasic Science Investigation
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma
Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I. Pettigrew, Dale J. Hamilton, Diego R. Martin and Zheng Li
Journal of Nuclear Medicine November 2022, 63 (11) 1708-1714; DOI: https://doi.org/10.2967/jnumed.121.263151
Zhen Yang
1Department of Radiology, Houston Methodist Academic Institute, Houston, Texas;
2Center for Bioenergetics, Houston Methodist Academic Institute, Houston, Texas;
Feng Li
1Department of Radiology, Houston Methodist Academic Institute, Houston, Texas;
2Center for Bioenergetics, Houston Methodist Academic Institute, Houston, Texas;
Yuqian Huang
2Center for Bioenergetics, Houston Methodist Academic Institute, Houston, Texas;
3Xiangya Hospital, Central South University, Hunan, China;
Na Yin
4Department of Pediatrics, Baylor College of Medicine, Houston, Texas;
Junjun Chu
5Department of Medicine, Kech School of Medicine, University of Southern California, Los Angeles, California;
Ying Ma
6NIBIB, NIH, Bethesda, Maryland;
Roderic I. Pettigrew
7Engineering Medicine, Texas A&M University, College Station, Texas;
Dale J. Hamilton
2Center for Bioenergetics, Houston Methodist Academic Institute, Houston, Texas;
8Department of Medicine, Weil Cornell Medicine, New York, New York; and
Diego R. Martin
1Department of Radiology, Houston Methodist Academic Institute, Houston, Texas;
9Department of Radiology, Weil Cornell Medicine, New York, New York
Zheng Li
1Department of Radiology, Houston Methodist Academic Institute, Houston, Texas;
2Center for Bioenergetics, Houston Methodist Academic Institute, Houston, Texas;
9Department of Radiology, Weil Cornell Medicine, New York, New York
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 11
November 1, 2022
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma
Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I. Pettigrew, Dale J. Hamilton, Diego R. Martin, Zheng Li
Journal of Nuclear Medicine Nov 2022, 63 (11) 1708-1714; DOI: 10.2967/jnumed.121.263151
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma
Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I. Pettigrew, Dale J. Hamilton, Diego R. Martin, Zheng Li
Journal of Nuclear Medicine Nov 2022, 63 (11) 1708-1714; DOI: 10.2967/jnumed.121.263151
Jump to section
Related Articles
Cited By...
- No citing articles found.